Education
About Us
Working with TipRanks
Follow Us
Certara (CERT)
NASDAQ:CERT
CERT Stock Chart & Stats
$12.51
-$0.37(-3.29%)
At close: 4:00 PM EST
$12.51
-$0.37(-3.29%)
Day’s Range― - ―
52-Week Range$8.64 - $15.69
Previous CloseN/A
Volume176.64K
Average Volume (3M)1.89M
Market Cap
$2.03B
Enterprise Value$2.03B
Total Cash (Recent Filing)$162.27M
Total Debt (Recent Filing)$307.86M
Price to Earnings (P/E)253.2
Beta1.45
Next Earnings
Nov 05, 2025EPS Estimate
0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.07
Shares Outstanding160,623,580
10 Day Avg. Volume1,632,701
30 Day Avg. Volume1,892,653
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.00
Enterprise Value/Revenue5.00
Enterprise Value/Gross Profit8.67
Enterprise Value/Ebitda41.00
Forecast
1Y Price Target
$15.33Price Target Upside22.54% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering8
Bulls Say, Bears Say
Bulls Say
Growth StrategyCertara is focused on reaccelerating growth by leaning into its software platform paired with its services offerings.
InnovationAI is in focus under newly appointed CTO Chris Bouton, with capabilities being embedded across the product stack.
Regulatory MilestoneCertara's PBPK modeling platform became the first and only software to receive European Medicines Agency qualification.
Bears Say
Customer PressuresThere are lingering headwinds to growth from pressures facing Life Sciences customers.
Market ConditionsManagement characterized the end-market as subdued, especially compared to the high funding environment during the pandemic.
Certara News
CERT FAQ
What was Certara’s price range in the past 12 months?
Certara lowest stock price was $8.63 and its highest was $15.69 in the past 12 months.
What is Certara’s market cap?
Certara’s market cap is $2.03B.
When is Certara’s upcoming earnings report date?
Certara’s upcoming earnings report date is Nov 05, 2025 which is in 6 days.
How were Certara’s earnings last quarter?
Certara released its earnings results on Aug 06, 2025. The company reported $0.07 earnings per share for the quarter, missing the consensus estimate of $0.1 by -$0.03.
Is Certara overvalued?
According to Wall Street analysts Certara’s price is currently Undervalued.
Does Certara pay dividends?
Certara does not currently pay dividends.
What is Certara’s EPS estimate?
Certara’s EPS estimate is 0.11.
How many shares outstanding does Certara have?
Certara has 160,623,580 shares outstanding.
What happened to Certara’s price movement after its last earnings report?
Certara reported an EPS of $0.07 in its last earnings report, missing expectations of $0.1. Following the earnings report the stock price went up 18.153%.
Which hedge fund is a major shareholder of Certara?
Currently, no hedge funds are holding shares in CERT
Certara Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$15.33 (22.54% Upside)
$15.33 (22.54% Upside)
Blogger Sentiment
Bullish
CERT Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 1.4M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 23.8%
Last 30 Days ▲ 23.8%
Technicals
SMA
Positive
20 days / 200 days
Momentum
22.64%
12-Months-Change
Fundamentals
Return on Equity
0.76%
Trailing 12-Months
Asset Growth
0.25%
Trailing 12-Months
Company Description
Certara
Certara, Inc. provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software, technology, and services to transform drug discovery and development. The company also provides related technology-enabled services to guide its customers' new drugs through the regulatory submission process and into the market. Its technology-enabled services include mechanistic biosimulation, empirical biosimulation, drug development and regulatory strategy, clinical pharmacology, model-based meta-analysis, regulatory writing and medical communications, regulatory operations, and market access. Further, company offers software, comprising mechanistic biosimulation platform, empirical PK/PD biosimulation platform, data standardization and compliance software, scientific informatics platform, clinical outcomes databases for biosimulation, authoring and management of regulatory submissions platform, and market access communication platform. The company serves biopharmaceutical companies, and academic and government institutions. It has operations in the United States, Canada, Spain, Luxembourg, Portugal, the United Kingdom, Germany, France, the Netherlands, Denmark, Switzerland, Italy, Poland, Japan, the Philippines, India, Australia, and China. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.
CERT Company Deck
CERT Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a strong performance in terms of revenue and bookings growth, driven by software, especially Simcyp, and significant regulatory achievements. However, there were concerns about timing issues with Tier 1 software renewals and macroeconomic challenges impacting customer decision-making. Despite these issues, the company's strong execution and positive outlook contributed to an overall positive sentiment.View all CERT earnings summariesCERT Stock 12 Month Forecast
Average Price Target
$15.33
▲(22.54% Upside)
Technical Analysis
Omnicell
―
Health Catalyst
―
Schrodinger
―
SOPHiA GENETICS
―
Definitive Healthcare Corp
―
Ownership Overview
2.24% Insiders
26.42% Mutual Funds
0.42% Other Institutional Investors
54.29% Public Companies and
Individual Investors